13-32394717-C-G
Variant summary
The NM_000059.4(BRCA2):c.9285C>G (p.Asp3095Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a cumulative frequency of 0.00000137 (AC=2) in the gnomAD database across 1,461,362 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.0000003. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★). ClinVar reports functional evidence for this variant: "SCV000073792: Experimental studies have shown that this missense change affects BRCA2 function (PMID:18451181, 22678057, 23108138)." and additional evidence is available in ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.D3095G: Conflicting_classifications_of_pathogenicity (ClinVar VariationId 409512) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.D3095A: Uncertain_significance (ClinVar VariationId 1330142, 1 star); p.D3095= (synonymous): Likely_benign (ClinVar VariationId 184910, 3 stars) This exact variant is established as oncogenic in: CGI (Cancer Genome Interpreter). This exact variant is curated in the UniProt human variants database as Uncertain Significance; it is also listed as a COSMIC curated somatic variant.
Frequency
Consequence
NM_000059.4 missense
Scores
Clinical Significance
Conservation
Publications
- BRCA2-related cancer predispositionInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- breast-ovarian cancer, familial, susceptibility to, 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- Fanconi anemia complementation group D1Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 2Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- sarcomaInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- medulloblastomaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
Classification according to ACMG Germline Pathogenicity v2019
Our verdict: Pathogenic. The variant received 21 points.
| Apply | Criterion Code & Title / Strength | Rationale / Clinical Context | |
|---|---|---|---|
| PS1Same amino acid change as known pathogenic | Same AA change, ≥2-star ClinVar pathogenic — very strong (PS1); ClinVar contains 1 P/LP entry with the same amino acid change (highest review level: 2 stars). | ||
| PS3Functional studies show damaging effect | Well-established functional study supports damaging effect (PS3); SCV000073792: Experimental studies have shown that this missense change affects BRCA2 function (PMID: 18451181, 22678057, 23108138).; SCV000695233: In these functional studies the variant was shown to cause significantly reduced HDR activity, increased aberrant centriole amplification, and reduced cell viability in null-rescue survival assays (example: Farrugia_2008, Biswas_2012, Guidugli_2012, Hart_2018, Mesman_2018, Ikegami_2020).; SCV001478279: The variant has a probability of pathogenicity of 1.0 (PS3_strong).; SCV006311323: Experimental studies have shown that this missense change affects BRCA2 function (PMID:18451181, 22678057, 23108138).; SCV000276898: A homology-directed DNA repair (HDR) assay has demonstrated this variant to be non-functional (Guidugli L et al. Am J Hum Genet 2018 02;102(2):233-248; Hart SN et al. Genet Med, 2019 01;21:71-80; Richardson ME et al. Am J Hum Genet 2021 03;108(3):458-468).; SCV000684048: Functional studies have shown that this variant disrupts homology-directed DNA repair activity (PMID: 18451181, 23108138, 29884841, 33609447) and fails to complement cell lethality phenotype induced by loss of BRCA2 in mouse embryonic stem cell-based assays (PMID: 24323938, 29988080, 37922907).; SCV000292530: Published functional studies demonstrate a damaging effect: reduced homology-directed repair (HDR) activity, aberrant centriole amplification, failure to rescue lethality of Brca2 null ES cells (Farruguia et al., 2008; Biswas et al., 2012; Guidugli et al., 2013; Ikegami et al., 2020; Richardson et al., 2021); SCV000600853: Published functional studies have shown that this variant results in a deleterious effect on BRCA2 protein function (PMID: 22678057 (2012), 29394989 (2018), 29988080 (2018)).; SCV005425843: Functional studies have shown that this variant disrupts homology-directed DNA repair activity (PMID: 18451181, 23108138, 29884841) and fails to complement cell lethality phenotype induced by loss of BRCA2 in mouse embryonic stem cell-based assays (PMID: 24323938, 29988080). | ||
| PM2Absent/extremely low in population databases | Very rare in gnomAD for AD/XL gene (popmax AF < threshold/10) — PM2; GnomAD popmax AF = 0.0000003 — very rare for AD+AR gene (base 0.0001, raised to 0.000139 by highest known P/LP ClinVar AF 0.000139) — PM2 moderate. | ||
| PM5Novel missense at known pathogenic residue | Different pathogenic missense at same AA residue in ClinVar (PM5); ClinVar contains a germline Pathogenic/Likely Pathogenic entry at the same amino acid position with a different amino acid change: p.D3095G: Conflicting_classifications_of_pathogenicity (ClinVar VariationId 409512); Other variants at the same amino acid residue (not pathogenic): p.D3095A: Uncertain_significance (ClinVar VariationId 1330142, 1 star); p.D3095= (synonymous): Likely_benign (ClinVar VariationId 184910, 3 stars) | ||
| PP3Computational evidence supports damaging effect | Germline meta computational scorer (REVEL/MetaRNN/BayesDel) predicts damaging effect — supporting evidence (PP3); Splicing verdict: not pathogenic.; Germline computational verdict: pathogenic (Supporting). | ||
| PP5Reputable source reports pathogenic | ClinVar 2-star pathogenic — strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 2 star(s). ClinVar submissions strongly and reliably favor pathogenicity (14/15 total P/LP). |
Variant Effect in Transcripts
Automated classification analysis was done for transcript: NM_000059.4. You can select a different transcript below to see updated classification assignments.
RefSeq Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
BRCA2 | MANE Select | c.9285C>G p.Asp3095Glu | missense | Exon 25 of 27 | Prot: NP_000050.3 UniProt: | |
BRCA2 | c.9285C>G p.Asp3095Glu | missense | Exon 25 of 27 | Prot: NP_001419006.1 UniProt: | ||
BRCA2 | c.9234C>G p.Asp3078Glu | missense | Exon 25 of 27 | Prot: NP_001393649.1 UniProt: |
Ensembl Transcripts
| Sel. | Gene / Transcript | Tags | HGVSc / HGVSp | Effect | Exon rank | Protein / UniProt |
|---|---|---|---|---|---|---|
BRCA2 | TSL:5MANE Select | c.9285C>G p.Asp3095Glu | missense | Exon 25 of 27 | Prot: ENSP00000369497.3 UniProt: | |
BRCA2 | TSL:1 | c.9285C>G p.Asp3095Glu | missense | Exon 25 of 27 | Prot: ENSP00000439902.1 UniProt: | |
BRCA2 | TSL:1 | c.8916C>G p.Asp2972Glu | missense | Exon 25 of 27 | Prot: ENSP00000499438.2 UniProt: |
Frequencies
Allele frequencies (AF), counts (AC/AN), homozygotes and coverage
| Source / population | AF | AC | Hom | AN | Coverage |
|---|---|---|---|---|---|
Global population databases 4 sources | |||||
GnomAD3 genomes | Cov:33 | ||||
GnomAD2 exomes | AF: 0.00000399 | AC:1 | AN:250672 | ||
GnomAD4 exome | AF: 0.00000137 | AC:2 | Hom:0 | AN:1461362 | Cov:31 |
GnomAD4 genome | Cov:33 | ||||
ClinVar
Computational Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
AlphaGenome AVI | Pathogenic | 21 | |
AlphaMissense | Pathogenic | 0.84 | |
BayesDel_addAF | Pathogenic | 0.40 | D |
BayesDel_noAF | Pathogenic | 0.34 | |
CADD | Benign | 16 | |
DANN | Uncertain | 0.99 | |
Eigen | Benign | 0.19 | |
Eigen_PC | Benign | 0.085 | |
FATHMM_MKL | Uncertain | 0.78 | D |
FuncVEP CTI | Pathogenic | 0.59 | |
GPN-Star LLR | N/A | -4.4 | |
GPN-Star score | N/A | 4.4 | |
M_CAP | Uncertain | 0.28 | D |
MetaRNN | Pathogenic | 0.96 | D |
MetaSVM | Uncertain | 0.66 | D |
Mutation Taster | N/A | 0/100 | disease causing (ClinVar) |
PhyloP100 | Benign | 1.5 | |
PrimateAI | Uncertain | 0.50 | T |
PROVEAN | Benign | -1.2 | N |
REVEL | Pathogenic | 0.69 | |
Sift | Pathogenic | 0.0 | D |
Sift4G | Uncertain | 0.023 | D |
VESM-3B | Benign | -11 |
Splicing Scores
| Algorithm | Calibrated pred. | Score | Prediction |
|---|---|---|---|
Pangolin (max) | Benign | 0.0 | |
SpliceAI score (max) | Benign | 0.0 | Details are displayed if max score is > 0.2 |
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.
MaveDB functional evidence
- Gene
- BRCA2
- Assay type
- Reporter
- Mechanism
- DNA repair and Double-strand break repair via homologous recombination
- Model system
- Other (Cricetulus griseus)
- Score
- 0.948 · p.Asp3095Glu (assay numbering)
- Gene
- BRCA2
- Score
- -3.76
- Gene
- BRCA2
- Score
- -0.878